A comparison of surgery and radiation therapy for XXXX @entity1721 .

@entity1 @entity129 @entity834 @entity7487 @entity5 @entity2910 @entity2396 @entity1721 @entity1576 @entity850 @entity1210
Surgery and radiation therapy have been used to treat @entity1721 . However, treatment outcomes have not yet been extensively investigated. The aim of this study was to compare surgery and radiation therapy for clinical T1 @entity1721 . A total of 67 clinical T1 @entity1721 @entity1 were treated between January 1997 and December 2005; 29 had undergone radical esophagectomy (surgery group) and 38 were treated with definitive radiation therapy (radiation group). The mean @entity1 age was lower in the surgery group than in the radiation group. In surgery group, @entity1576 , @entity834 , recurrent @entity129 , and @entity850 occurred in 7, 8, 6, and 5 @entity1 , respectively. In radiation group, @entity1210 , @entity2910 , @entity2396 were observed in 15, 3, and 3 @entity1 , respectively. The 5-year overall survival rate for the surgery group was 68.9%, and 74.3% for the radiation group. There were no significant difference between groups (P= 0.3780). The 5-year relapse-free survival rate in the surgery group was 61.8% and 38.8% in the radiation group. The relapse-free survival rate was significantly higher in the surgery group than in the radiation group (P= 0.0051). The 5-year overall and relapse-free survival rates for @entity5 invaded into but not through the muscularis mucosa were 83.3% and 75.0%, respectively, in the surgery group and 78.8% and 33.3%, respectively, in the radiation group. There were no significant differences. The 5-year overall survival rates for @entity1 with @entity5 that invaded the submucosal layer was 64.9% in the surgery group and 66.5% in the radiation group. This difference was not significant (P= 0.8712). The 5-year relapse-free survival rate in the surgery group (56.0%) was significantly higher than that in the radiation group (41.8%; P= 0.0219). In conclusion, surgery may become a standard treatment for @entity7487 esophageal cancer that can offer longer relapse-free survival, particularly for @entity1 with @entity5 that invade the submucosa.
